DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Open Access
- 1 April 2015
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 194 (7) , 3201-3212
Abstract
NK cells are emerging as new effectors for immunotherapy of cancer. In particular, the genetic engraftment of chimeric Ag receptors (CARs) in NK cells is a promising strategy to redirect NK cells to otherwise NK cell–resistant tumor cells. On the basis of DNAX-activation protein 12 (DAP12), a signaling adaptor molecule involved in signal transduction of activating NK cell receptors, we generated a new type of CAR targeting the prostate stem cell Ag (PSCA). We demonstrate in this article that this CAR, designated anti–PSCA-DAP12, consisting of DAP12 fused to the anti-PSCA single-chain Ab fragment scFv(AM1) confers improved cytotoxicity to the NK cell line YTS against PSCA-positive tumor cells when compared with a CAR containing the CD3ζ signaling chain. Further analyses revealed phosphorylation of the DAP12-associated ZAP-70 kinase and IFN-γ release of CAR-engineered cells after contact with PSCA-positive target cells. YTS cells modified with DAP12 alone or with a CAR bearing a phosphorylation-defective ITAM were not activated. Notably, infused YTS cells armed with anti–PSCA-DAP12 caused delayed tumor xenograft growth and resulted in complete tumor eradication in a significant fraction of treated mice. The feasibility of the DAP12-based CAR was further tested in human primary NK cells and confers specific cytotoxicity against KIR/HLA-matched PSCA-positive tumor cells, which was further enhanced by KIR-HLA mismatches. We conclude that NK cells engineered with DAP12-based CARs are a promising tool for adoptive tumor immunotherapy.Keywords
This publication has 70 references indexed in Scilit:
- T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2 + prostate and breast cancer cellsProceedings of the National Academy of Sciences, 2012
- Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene TherapyHuman Gene Therapy, 2012
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2bJournal of Immunotherapy, 2010
- Activation of transgenic estrogen receptor-beta by selected phytoestrogens in a stably transduced rat serotonergic cell lineThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- TREM and TREM-like receptors in inflammation and diseaseCurrent Opinion in Immunology, 2009
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomasProceedings of the National Academy of Sciences, 2008
- Overcoming obstacles to the effective immunotherapy of human cancerProceedings of the National Academy of Sciences, 2008
- Up on the tightrope: natural killer cell activation and inhibitionNature Immunology, 2008
- CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequenceJournal of Experimental Medicine, 2008
- Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivoCancer Gene Therapy, 2002